Literature DB >> 10699469

Identification by RNA-based arbitrarily primed PCR of the involvement of cytochrome c oxidase in the development of resistance to methotrexate.

C Alemany1, V Noe, C J Ciudad.   

Abstract

RNA-based arbitrarily primed PCR (RAP-PCR) was used to identify sequences in CHO K1 cells that were differentially expressed upon methotrexate incubation during the development of resistance to this drug. Ten different RAP products were isolated, cloned and sequenced. Among these, we identified one sequence that showed 84% identity with the nucleotide sequence of rat cytochrome c oxidase subunit II, and 90% identity with the amino acid sequence of this protein. This RAP fragment was up-regulated in a dose- and time-dependent manner. The overexpression of cytochrome c oxidase subunit II mRNA as a result of methotrexate incubation was corroborated by quantitative RT-PCR and Northern blot analysis. Incubation of cells with sodium azide, a specific cytochrome c oxidase inhibitor, decreased the number of resistant colonies after methotrexate treatment. Thus, overexpression of cytochrome c oxidase is involved in the development of resistance to methotrexate. These results suggest that sodium azide may be used as a modulator in chemotherapy with methotrexate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699469     DOI: 10.1016/s0167-4889(99)00159-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Transcriptomic and proteomic responses of sweetpotato whitefly, Bemisia tabaci, to thiamethoxam.

Authors:  Nina Yang; Wen Xie; Xin Yang; Shaoli Wang; Qingjun Wu; Rumei Li; Huipeng Pan; Baiming Liu; Xiaobin Shi; Yong Fang; Baoyun Xu; Xuguo Zhou; Youjun Zhang
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

2.  First comparative transcriptomic analysis of wild adult male and female Lutzomyia longipalpis, vector of visceral leishmaniasis.

Authors:  Christina B McCarthy; María Soledad Santini; Paulo F P Pimenta; Luis A Diambra
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.